9 results about "No release" patented technology

This invention provides a chlorambucil NO donor prodrug having the structure shown in Formula (I) or a pharmaceutically acceptable salt thereof: Formula (I). It involves reacting chlorambucil with a dihaloalkane to obtain a halochlorambucil intermediate; reacting the halochlorambucil intermediate with silver nitrate to obtain the chlorambucil NO donor prodrug. This invention applies the chlorambucil NO donor prodrug to the preparation of drugs for treating tumors, such as melanoma, lymphoma, leukemia, or breast cancer. This nanosystem exhibits good NO release levels under light irradiation. Cellular experiments have demonstrated its good antitumor effect, providing a new strategy for multimodal combined antitumor therapy.

The invention discloses a degradable magnesium alloy intravascular stent based on bionic hydrogel and nitric oxide double-path release and a preparation method and application thereof. The method comprises the steps that a magnesium alloy base material is subjected to alkali heat treatment; immersing the treated magnesium alloy into a silane coupling agent for reaction; the photopolymerization reaction liquid is treated to the surface of the silanization modified magnesium alloy, and polymerization is conducted through ultraviolet irradiation; immersing the magnesium alloy with the hydrogel coating into a polyarginine solution, and grafting polyarginine onto the surface of the hydrogel; a sample is activated through EDC / NHS and then immersed in a selenocystamine solution for a reaction, and the bionic composite coating, with the exogenous / endogenous dual-path nitric oxide release function, of the degradable magnesium alloy intravascular stent is obtained. The invention successfully constructs the bionic coating integrating cell membrane-imitating anti-fouling and exogenous / endogenous dual-path NO release functions, and the coating effectively solves the key problems of corrosion control, thrombus formation resistance, functional re-endothelialization coordinated regulation and the like faced by the degradable magnesium alloy intravascular stent.

The present application relates to a kind of nano-drugs with eNOS-like enzyme activity and its preparation method and application, belong to nano-drug technical field.Solve the technical problems that drug cannot pass through blood-brain barrier and cannot simultaneously inhibit neuron calcium overload, reduce mitochondrial damage and endoplasmic reticulum stress, inhibit inflammatory storm and other multiple effects in prior art.The nano-drug of the present application is the NO embedded molybdenum sulfide nanomaterial obtained by introducing S-nitroso group on the surface of small particle molybdenum sulfide.The nano-drug prepared by the present application has super strong antioxidant activity and stable NO release capacity, can effectively target CIRI brain tissue damage and stable release pure NO, can effectively treat cerebral ischemia-reperfusion injury, while improving intracellular Ca 2+ Overload, oxidative stress and inflammatory storm, can effectively protect neuron mitochondria from overload Ca 2+ And mtROS Damage, and significantly restore mitochondrial function in CIRI and other advantages.

The application discloses a kind of photonic nitric oxide donor with fluorescent self-reporting function and its preparation method and application, belong to the field of biomedical materials.The nitric oxide donor has the structure as shown in formula 1.The donor itself weak fluorescence, but in the presence of reduced glutathione (GSH), after irradiation by ultraviolet light (such as 405 nm), it can efficiently and controllably release nitric oxide (NO), and it is accompanied by strong fluorescence enhancement signal (fluorescence intensity can be increased by about 100 times), so as to realize the real-time, high-resolution fluorescence monitoring of NO release process and site.The donor has good light stability and biocompatibility.Experiments show that it can realize the light-controlled release and imaging of NO in living cells, and has application potential in the field of biomedical research and related drug development.

The invention relates to a pharmaceutical composition for promoting local tissue nitric oxide release level increase and application of the pharmaceutical composition, the pharmaceutical composition comprises monoterpene alcohol and monoterpene, and the weight ratio of the monoterpene alcohol to the monoterpene is 10: 1-1: 10. The pharmaceutical composition disclosed by the invention has the advantages of strong adhesion, remarkable effect, convenience in use, high safety and the like, and can be used for remarkably increasing the NO release level of target tissues and improving the life quality of a user.

In the method of the present application, the physiological state of the subject can be tracked by studying the NO release profile of the subject, wherein said NO release profile is obtained by measuring the subject's skin by the sensing element during a predetermined sequence of activities.

The application provides a polypeptide and application thereof in preparation of anti-inflammatory products. The application finds that the polypeptide with the amino acid sequence shown in SEQ ID NO:1 not only has high safety, but also can significantly reduce the influence of LPS on NO release and secretion of inflammatory factors of macrophages, which indicates that the polypeptide has excellent anti-inflammatory activity and is suitable for preparation of anti-inflammatory products (such as pharmaceutical products, daily chemical products and the like). Therefore, the application not only enriches an anti-inflammatory peptide resource library, but also provides more raw material selection for anti-inflammatory products.

The present invention provides a patch-type thrombus monitoring and NO release closed-loop system for treating venous thrombosis. The system comprises: a flexible patch substrate integrated with: a sensor module comprising a blood flow velocity sensor, a bioimpedance sensor, an acceleration sensor, and a temperature sensor, each for acquiring blood flow velocity v at the target vein, parameters related to vascular resistance R, limb motion status, and skin temperature in the patch area; an NO release module for releasing NO to act on the venous thrombosis site; a control module comprising a signal processing unit and a control unit, which receives signals output by the sensor module and runs a closed-loop control algorithm to generate NO release control instructions; and a power supply module for providing power to the sensor module, the control module, and the NO release module. This system integrates multimodal thrombus monitoring, decision-making, assisted NO release, and adaptive switching of treatment modes.

This invention relates to cinacalcet hydrochloride, specifically to its application in the preparation of drugs for treating allergic rhinitis. This invention is the first to discover that cinacalcet hydrochloride has a therapeutic effect on allergic rhinitis. Specifically, drugs that effectively inhibit NO release from RAW264.7 cells (an in vitro inflammation model was established using LPS stimulation of RAW264.7 cells) were screened from 1430 FDA-approved small molecule compounds, and cinacalcet hydrochloride was discovered for the first time to dose-dependently inhibit NO release in the in vitro inflammation model. Furthermore, in vivo therapeutic experiments also showed that cinacalcet hydrochloride effectively inhibits the release of allergic mediators in vivo without affecting the body weight of mice, demonstrating good safety.